AU2011252127B2 - Process for the preparation of insulin-zinc complexes - Google Patents

Process for the preparation of insulin-zinc complexes Download PDF

Info

Publication number
AU2011252127B2
AU2011252127B2 AU2011252127A AU2011252127A AU2011252127B2 AU 2011252127 B2 AU2011252127 B2 AU 2011252127B2 AU 2011252127 A AU2011252127 A AU 2011252127A AU 2011252127 A AU2011252127 A AU 2011252127A AU 2011252127 B2 AU2011252127 B2 AU 2011252127B2
Authority
AU
Australia
Prior art keywords
insulin
cooh
chain
process according
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011252127A
Other languages
English (en)
Other versions
AU2011252127A1 (en
Inventor
Lene Andresen
Rosa Rebecca Erritzoe Hansen
Per Jeppesen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of AU2011252127A1 publication Critical patent/AU2011252127A1/en
Application granted granted Critical
Publication of AU2011252127B2 publication Critical patent/AU2011252127B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2011252127A 2010-05-10 2011-05-09 Process for the preparation of insulin-zinc complexes Ceased AU2011252127B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10162368.4 2010-05-10
EP10162368 2010-05-10
US33349710P 2010-05-11 2010-05-11
US61/333,497 2010-05-11
PCT/EP2011/057388 WO2011141407A1 (en) 2010-05-10 2011-05-09 Process for the preparation of insulin-zinc complexes

Publications (2)

Publication Number Publication Date
AU2011252127A1 AU2011252127A1 (en) 2012-11-01
AU2011252127B2 true AU2011252127B2 (en) 2014-02-20

Family

ID=42732779

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011252127A Ceased AU2011252127B2 (en) 2010-05-10 2011-05-09 Process for the preparation of insulin-zinc complexes

Country Status (12)

Country Link
US (5) US20130143803A1 (enExample)
EP (1) EP2569002B1 (enExample)
JP (2) JP6249773B2 (enExample)
KR (2) KR20130092972A (enExample)
CN (2) CN102883743A (enExample)
AU (1) AU2011252127B2 (enExample)
BR (1) BR112012028766A2 (enExample)
CA (1) CA2795091A1 (enExample)
ES (1) ES2612468T3 (enExample)
MX (1) MX2012012943A (enExample)
RU (1) RU2572214C2 (enExample)
WO (1) WO2011141407A1 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9034818B2 (en) 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
US9603904B2 (en) 2008-10-30 2017-03-28 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
US10596229B2 (en) 2010-10-27 2020-03-24 Novo Nordisk A/S Method of treating diabetes mellitus by administration, at specifically defined intervals, of a derivative of a naturally occurring insulin or insulin analogue, the derivative having a prolonged profile of action
US11167035B2 (en) 2005-12-28 2021-11-09 Novo Nordisk A/S Insulin compositions and method of making a composition
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2256130B1 (en) 2005-02-02 2013-09-25 Novo Nordisk A/S Novel insulin derivatives
DE602007009496D1 (de) 2006-02-27 2010-11-11 Novo Nordisk As Insulinderivate
MX2008014061A (es) * 2006-05-09 2008-11-14 Novo Nordisk As Derivado de insulina.
EP2024390B1 (en) 2006-05-09 2015-08-19 Novo Nordisk A/S Insulin derivative
CN101932601B (zh) 2007-11-08 2016-08-03 诺沃-诺迪斯克有限公司 胰岛素衍生物
JP6755175B2 (ja) * 2013-03-20 2020-09-16 ノヴォ ノルディスク アー／エス インスリン投薬レジメン
PT3055325T (pt) * 2013-10-07 2018-04-06 Novo Nordisk As Novo derivado de um análogo de insulina
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
ES2630106T3 (es) 2014-10-07 2017-08-18 Cyprumed Gmbh Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos
EP3740195A1 (fr) * 2017-12-07 2020-11-25 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
IL275146B2 (en) 2017-12-07 2025-01-01 Adocia Preparations in the form of an aqueous solution for injection comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid
TWI740099B (zh) * 2018-02-01 2021-09-21 大陸商江蘇恒瑞醫藥股份有限公司 含人胰島素類似物的醯化衍生物的藥物組合物及其製備方法
TWI742377B (zh) 2018-05-24 2021-10-11 大陸商江蘇恒瑞醫藥股份有限公司 一種重組人胰島素或其類似物的前驅物的製備方法
BR112021011050A2 (pt) 2018-12-11 2021-08-31 Sanofi Ligante peptídico

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1042194A (en) * 1962-04-30 1966-09-14 Olin Mathieson Insulin preparations
US3868358A (en) * 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
WO2008152106A1 (en) * 2007-06-13 2008-12-18 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
US20090312236A1 (en) * 2008-06-13 2009-12-17 John Michael Beals Pegylated insulin lispro compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1212679B (de) * 1957-08-03 1966-03-17 Novo Terapeutisk Labor As Verfahren zur Herstellung von Insulinloesungen
DK113585D0 (da) * 1985-03-12 1985-03-12 Novo Industri As Nye peptider
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US4764592A (en) * 1987-04-23 1988-08-16 Eli Lilly And Company Crystalline human proinsulin and process for its production
WO1990007522A1 (en) 1988-12-23 1990-07-12 Novo Nordisk A/S Human insulin analogues
IL93282A (en) 1989-02-09 1995-08-31 Lilly Co Eli Insulin analogues
DE122004000035I2 (de) * 1993-09-17 2009-08-06 Novo Nordisk As Acyliertes insulin
US7097845B2 (en) * 1997-04-23 2006-08-29 Jacob Sten Petersen Combinations of antigen and mucosal binding component for inducing specific immunological tolerance
PT2107069E (pt) * 2003-08-05 2013-04-23 Novo Nordisk As Novos derivados de insulina
EP2107069B1 (en) 2003-08-05 2013-01-16 Novo Nordisk A/S Novel insulin derivatives
EP2505593A1 (en) * 2005-12-28 2012-10-03 Novo Nordisk A/S Compositions comprising an acylated insulin and zinc and method of making the said compositions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1042194A (en) * 1962-04-30 1966-09-14 Olin Mathieson Insulin preparations
US3868358A (en) * 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
WO2008152106A1 (en) * 2007-06-13 2008-12-18 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
US20090312236A1 (en) * 2008-06-13 2009-12-17 John Michael Beals Pegylated insulin lispro compounds

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11167035B2 (en) 2005-12-28 2021-11-09 Novo Nordisk A/S Insulin compositions and method of making a composition
US9034818B2 (en) 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
US9603904B2 (en) 2008-10-30 2017-03-28 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
US10596229B2 (en) 2010-10-27 2020-03-24 Novo Nordisk A/S Method of treating diabetes mellitus by administration, at specifically defined intervals, of a derivative of a naturally occurring insulin or insulin analogue, the derivative having a prolonged profile of action
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
US12226458B2 (en) 2018-06-26 2025-02-18 Novo Nordisk A/S System for providing an up-to-date and long-acting or ultra-long-acting insulin dose guidance recommendation to treat diabetes mellitus
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation

Also Published As

Publication number Publication date
MX2012012943A (es) 2012-11-29
ES2612468T3 (es) 2017-05-17
CN102883743A (zh) 2013-01-16
CA2795091A1 (en) 2011-11-17
EP2569002A1 (en) 2013-03-20
KR20160105979A (ko) 2016-09-08
US20210060132A1 (en) 2021-03-04
US20150250857A1 (en) 2015-09-10
AU2011252127A1 (en) 2012-11-01
US20240307503A1 (en) 2024-09-19
EP2569002B1 (en) 2016-10-26
WO2011141407A1 (en) 2011-11-17
KR20130092972A (ko) 2013-08-21
US20170165327A1 (en) 2017-06-15
JP6249773B2 (ja) 2017-12-20
JP2017203042A (ja) 2017-11-16
JP2013526501A (ja) 2013-06-24
BR112012028766A2 (pt) 2017-06-13
CN107029212A (zh) 2017-08-11
US20130143803A1 (en) 2013-06-06
RU2012148821A (ru) 2014-06-20
RU2572214C2 (ru) 2015-12-27

Similar Documents

Publication Publication Date Title
AU2011252127B2 (en) Process for the preparation of insulin-zinc complexes
US9603904B2 (en) Treating diabetes melitus using insulin injections with less than daily injection frequency
ES2360505T3 (es) Preparados de insulina libre de zinc o con bajo contenido en cinc con estabilidad mejorada.
JP6111475B2 (ja) ヒトインスリン又はその類似体もしくは誘導体を含む安定な水性組成物
US20130261051A1 (en) Treating Diabetes Melitus Using Insulin Injections Administered With Varying Injection Intervals
CN102665676B (zh) 非共价结合的白蛋白和酰化胰岛素的药物溶液
US10596229B2 (en) Method of treating diabetes mellitus by administration, at specifically defined intervals, of a derivative of a naturally occurring insulin or insulin analogue, the derivative having a prolonged profile of action
IT8223018A1 (it) Formulazioni farmaceutiche comprendenti insulina, c-peptide e pro-insulina umani

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired